Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence
A cluster-randomized double-blinded control trial will be conducted in Uganda to demonstrate and quantify the protective efficacy (PE) of Mossie-GO, an active spatial repellent system disseminating transfluthrin, in reducing the prevalence of malaria in children ≤ 5 years of age, as determined by RDT positivity and con
| Condition(s) | Malaria, Mosquito-Borne Disease |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | A cluster-randomized double-blinded control trial will be conducted in Uganda to demonstrate and quantify the protective efficacy (PE) of Mossie-GO, an active spatial repellent system disseminating transfluthrin, in reducing the prevalence of malaria in children ≤ 5 years of age, as determined by RDT positivity and confirmed by microscopy. The study's secondary objective is to measure the diversionary impact of the intervention on locally unprotected individuals and impact of the intervention on entomological correlates of transmission including vector densities, host seeking behaviour and insecticide resistance. This will be conducted using Centre of Disease Control (CDC) light traps in households, human landing catches and World Health Organisation (WHO) tube tests. Further data collecti |
| Who can participate | Inclusion Criteria: Cluster level: Number of households \> 100 Household level: Presence of a child ≤ 5 years of age at point of enrolment in the study Adult head of household agrees to receiving and using the device as per manual instructions Adult head of household agrees to data collection visits and household surveys Children within household sleeps in cluster \> 90% of nights during any given month Individual level: ≤ 5 years of age when enrolled into the study No plans for extended travel (\> 1 month) outside of home during study Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial Provision of informed consent form (ICF) by the parent(s) or guardian Participants not on regular malaria prophylaxis Exclusion |
| Ages | 5 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Africa Power Limited |
| Locations | Jinja, Uganda |
| Start date | 2024-06-05 |
| NCT ID | NCT06232954 |
| Official listing | https://clinicaltrials.gov/study/NCT06232954 |